摘要
目的探讨怡诺思治疗广泛性焦虑症的临床疗效和安全性.方法将68例广泛性焦虑症患者随机分为怡诺思组34例和阿普唑仑组34例.怡诺思组治疗剂量75～150mg·d^-1,阿普唑仑组为1.2～3.6mg·d^-1观察时间均为6w.治疗前与治疗第1,2,4,6w末采用汉密顿焦虑量表、焦虑自评量表、副反应量表评定临床疗效和副反应.结果两组疗效相当,差异无显著性（P＞0.05）;阿普唑仑组起效时间快于怡诺思组,但远期疗效差于怡诺思组;怡诺思组副反应明显少于阿普唑仑组（P＜0.05）.结论怡诺思治疗广泛性焦虑疗效肯定,安全性高,依从性好.
Objective To explore the clinical efficacy and safety of venlafaxine in generalized anxiety. Methods 68 patients with generalized anxiety were randomly divided into venlafaxine and alpralid group （each n= 34）. Dosage of the venlafaxine was 75 - 150mg/day and the alpralid 1, 2 - 3, 6mg/day for 6 weeks. Clinical efficacy and side effects were assessed using Hamilton Anxiety Rating Scale（HAMA）,the Self-rating Anxiety Scale（SAS） and the Treatment Emergent at the ends of lst,2nd ,4th and 6th week treatment. Results Symptom Scale（TESS） before treatment and Efficacies of the 2 groups were equivalent and difference wasn＇t significant（P〉0.05） ; alpralid took effect faster than venlafaxine did, but its long- term efficacy was poor; side effects of the venlafaxine was significantly fewer than those of the alpralid（P 〈0.05）. Conclusion Venlafaxine has better efficacy, higher safety and compliance in the treatment of generalized anxiety.
出处
《临床心身疾病杂志》
CAS
2006年第3期190-191,共2页
Journal of Clinical Psychosomatic Diseases
